Salona Global Medical Device Corporation (LNDZF) fair value: what the stock is really worth
As of Jun 25, 2026: fair value of Salona Global Medical Device Corporation $0.00, price $0.00, upside +0.0%, quality 27 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Salona Global Medical Device Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Evome Medical Technologies Inc. designs, develops, produces, and sells medical devices in the United States. The company was formerly known as Salona Global Medical Device Corporation and changed its name to Evome Medical Technologies Inc. in January 2024. The company is based in Shirley, New York.
Stock analysis
Salona Global Medical Device Corporation (LNDZF) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Salona Global Medical Device Corporation reported revenue of C$62.6M in FY2024 versus −C$33.5K in FY2020. Reported net income was −C$15.6M in FY2024.
Key figures
Market cap $8.9K · EPS (TTM) $−0.2100 · Net margin −24.9% · Return on equity −295% · Return on assets (EBIT) −9.0% · Operating margin −4.6% · Revenue (TTM) C$48.3M · Revenue growth (YoY) −49.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 0%, LNDZF screens richer than that median.
Fair Value models
Bear $0.0001Fair Value $0.0001Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+58.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+181.8%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+67.6%
’14
’15
’16
’17
’18
’19
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−479.5% (2019) → −8.8% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
Compare Salona Global Medical Device Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score27 · Bottom 25%
Fair Value upside+0.0% · Above median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−6.7% · Below median
Net margin (TTM)−48.7% · Bottom 25%
Operating margin (TTM)−4.6% · Bottom 25%
Growth and dividend
Revenue growth−49.0% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Salona Global Medical Device Corporation Fair Value". https://www.fairvalue-calculator.com/stock/LNDZF
Frequently asked questions
Is Salona Global Medical Device Corporation (LNDZF) overvalued or undervalued?
As of Jul 5, 2026, our model estimates a fair value of $0.0001 versus the last price from Jun 25, 2026 of $0.0001, about +0% upside (fairly valued).
What is the fair value of LNDZF?
Our model-based fair value for Salona Global Medical Device Corporation is $0.0001 (as of Jul 5, 2026), built from audited fundamentals. Last price (from Jun 25, 2026): $0.0001.
What is the quality score of LNDZF?
Salona Global Medical Device Corporation has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Salona Global Medical Device Corporation (LNDZF)?
Our model-based price target is the fair value of $0.0001 (as of Jul 5, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Salona Global Medical Device Corporation stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus the last price from Jun 25, 2026 of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Salona Global Medical Device Corporation (LNDZF)?
Salona Global Medical Device Corporation reported trailing-twelve-month revenue of about C$48.3M (latest available figure, as of Jul 5, 2026).
What is the intrinsic value of Salona Global Medical Device Corporation (LNDZF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Salona Global Medical Device Corporation it is $0.0001 per share (as of Jul 5, 2026), against a price of $0.0001. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Salona Global Medical Device Corporation stock overvalued or undervalued in 2026?
As of Jul 5, 2026, LNDZF trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LNDZF?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Salona Global Medical Device Corporation the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Salona Global Medical Device Corporation worth?
The market values Salona Global Medical Device Corporation at about $8.9K (market capitalisation, as of Jul 5, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of Salona Global Medical Device Corporation (LNDZF)?
Balance-sheet figures for Salona Global Medical Device Corporation (as of Jul 5, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
Which stocks are comparable to Salona Global Medical Device Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Salona Global Medical Device Corporation stock attractive at the current price?
The data as of Jul 5, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LNDZF calculated?
We run Salona Global Medical Device Corporation through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Salona Global Medical Device Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Salona Global Medical Device Corporation (LNDZF)?
The latest price we hold is from Jun 25, 2026 and stands at $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Salona Global Medical Device Corporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Salona Global Medical Device Corporation
How large is the market capitalisation of Salona Global Medical Device Corporation (LNDZF)?
The market capitalisation of Salona Global Medical Device Corporation is $8.9K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Salona Global Medical Device Corporation (LNDZF)?
Earnings per share at Salona Global Medical Device Corporation are $−0.2100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Salona Global Medical Device Corporation (LNDZF)?
The net margin of Salona Global Medical Device Corporation is −24.9% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Salona Global Medical Device Corporation (LNDZF)?
The return on equity (ROE) of Salona Global Medical Device Corporation is −295% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Salona Global Medical Device Corporation (LNDZF)?
On an EBIT basis the return on assets of Salona Global Medical Device Corporation is −9.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Salona Global Medical Device Corporation (LNDZF)?
The operating margin of Salona Global Medical Device Corporation is −4.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Salona Global Medical Device Corporation (LNDZF)?
Revenue at Salona Global Medical Device Corporation is growing −49.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Salona Global Medical Device Corporation (LNDZF)?
Earnings per share at Salona Global Medical Device Corporation are growing −36.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Salona Global Medical Device Corporation (LNDZF) generate?
The free cash flow of Salona Global Medical Device Corporation is −C$1.1M (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Salona Global Medical Device Corporation (LNDZF) carry?
The net debt of Salona Global Medical Device Corporation is C$23.8M (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Salona Global Medical Device Corporation in the live analysis
One click puts Salona Global Medical Device Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Jul 5, 2026